Stimulation of autophagy suppresses the intracellular survival of Burkholderia pseudomallei in mammalian cell lines.
Burkholderia pseudomallei is the causative agent of melioidosis, a tropical infection of humans and other animals. The bacterium is an intracellular pathogen that can escape from endosomes into the host cytoplasm, where it replicates and infects adjacent cells. We investigated the role played by autophagy in the intracellular survival of B. pseudomallei in phagocytic and non-phagocytic cell lines. Autophagy was induced in response to B. pseudomallei invasion of murine macrophage (RAW 264.7) cells and a proportion of the bacteria co-localized with the autophagy effector protein LC3, a marker for autophagosome formation. Pharmacological stimulation of autophagy in RAW 264.7 and murine embryonic fibroblast (MEF) cell lines resulted in increased co-localization of B. pseudomallei with LC3 while basal levels of co-localization could be abrogated using inhibitors of the autophagic pathway. Furthermore, induction of autophagy decreased the intracellular survival of B. pseudomallei in these cell lines, but bacterial survival was not affected in MEF cell lines deficient in autophagy. Treatment of infected macrophages with chloramphenicol increased the proportion of bacteria within autophagosomes indicating that autophagic evasion is an active process relying on bacterial protein synthesis. Consistent with this hypothesis, we identified a B. pseudomallei type III secreted protein, BopA, which plays a role in mediating bacterial evasion of autophagy. We conclude that the autophagic pathway is a component of the innate defense system against invading B. pseudomallei, but which the bacteria can actively evade. However, when autophagy is pharmacologically induced using rapamycin, bacteria are actively sequestered in autophagosomes, ultimately decreasing their survival.
Cullinane
Méabh
M
Australian Bacterial Pathogenesis Program, Monash University, Clayton campus, Victoria, Australia.
Gong
Lan
L
Li
Xuelei
X
Lazar-Adler
Natalie
N
Tra
Thien
T
Wolvetang
Ernst
E
Prescott
Mark
M
Boyce
John D
JD
Devenish
Rodney J
RJ
Adler
Ben
B
D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001343:Autophagy / Q000187:drug effects / Q000502:physiology*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D016957:Burkholderia pseudomallei / Q000166:cytology / Q000472:pathogenicity / Q000502:physiology*; D002460:Cell Line / Q000382:microbiology*; D002470:Cell Survival; D006801:Humans; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D020123:Sirolimus / Q000494:pharmacology; D000077191:Wortmannin
D000730:Androstadienes; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D011993:Recombinant Fusion Proteins; D020123:Sirolimus; D000077191:Wortmannin